Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Development of a novel human derived probiotic species platform - Phase 1

Descrizione del progetto

Una piattaforma per i probiotici di origine umana

Il mercato dei probiotici sta crescendo in tutto il mondo a causa dell’entusiasmante potenziale offerto dai probiotici di prossima generazione (NGP, next-generation probiotics) per la prevenzione e il trattamento di malattie specifiche. Sebbene i probiotici tradizionali abbiano principalmente origine non umana e producano effetti positivi limitati, gli NGP sono di derivazione umana e svolgono un ruolo fondamentale nel mantenere i microbioti in condizioni di salute. Ciononostante, lo sviluppo di prodotti NGP ha bisogno di nuove tecniche avanzate di coltura e produzione. Il progetto NOVOBIOME-1, finanziato dall’UE, propone una piattaforma che copre l’intero ciclo di produzione degli NGP applicando innovativi modelli e processi tecnologici per accelerare la procedura di immissione sul mercato. Il progetto analizzerà i prerequisiti per massimizzare la commercializzazione nel mercato europeo.

Obiettivo

The global probiotics market is flourishing and anticipated to grow substantially in the coming years due the highly promising application of next-generation probiotics (NGPs) as live biotherapeutic products (LBPs). Whereas traditional probiotics are mainly derived from non-human origins with limited positive effects, NGPs are human-derived and play a key role in a healthy microbiota. All major probiotic companies are now moving into this field, however they are struggling with product development due to the intrinsic properties of NGPs. As a result, no NGP products have successfully reached the market yet. NGP product development requires radically new techniques for cultivation and production. This untapped market segment is highly attractive for Winclove. To tackle this problem, Winclove is developing the NOVOBIOME platform – covering the full cycle of NGP product development. Winclove’s approach leverages its already functional in-house facilities and infrastructure and combines it with innovative models and technological methods that can fast-track the timeline of NGP product to market for our clients. Winclove, an innovative Dutch SME, is a leader in microbiota-management, which has
been offering services in research, development and manufacturing of probiotic formulations for over 25 years. Winclove has been very successful in growing the company into a sustainable business with 73 FTE, growing 14% per annum on average. It provides its services to over 80 customers in 35 countries worldwide. As such, it has sold via its clients over 130 million daily dosages in 2018. Winclove aims to provide the NOVOBIOME platform as a B2B fee for service to dedicated innovative companies that are working on NGP-based LBPs. Winclove anticipates to generate €8M in turnover within the first 5 years of commercializing the NOVOBIOME platform. This SME-1 instrument project NOVOBIOME phase 1 enables Winclove to investigate the requirements to maximize the European commercialization

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-EIC-SMEInst-2018-2020

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

WINCLOVE BV
Contributo netto dell'UE
€ 50 000,00
Indirizzo
HULSTWEG 11
1032 LB AMSTERDAM
Paesi Bassi
PMI
Sì
Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00